Aho A J, Mäenpää J U, Kangas L, Söderström K O, Auranen A A, Linna M
Eur J Cancer Clin Oncol. 1985 Oct;21(10):1133-40. doi: 10.1016/0277-5379(85)90004-5.
The subrenal capsule assay (SRCA) was used to study the sensitivity of breast cancer to cytostatic drug combinations. The results were compared with steroid receptor status. Forty-five of 46 SRCAs (98%) were macroscopically evaluable. However, a histological study implied that the transplants should also be evaluated histologically, because in only 14/21 (67%) of the control SRCAs examined were histologically viable tumor cells seen. An inflammatory cell reaction was noticed in half of the cases. In the groups treated with cytostatics only 3/21 (14%) had vital tumor cells, whereas inflammation was evident in 4/21 (19%) of the cases. The rate of resistance to A + CTX was 30%. By testing several drug combinations against each tumor the rate of chemoresistance was reduced to 10%. The differences between A + CTX and the best combination were statistically significant (P less than 0.05). Of the tumors 79% were ER-positive and 67% PR-positive. Receptor-negative tumors tended to be more sensitive to cytostatics than receptor-positive tumors (100 vs 85%). The difference was not, however, statistically significant. It can be concluded that the SRCA under standardized conditions is a good method for studying the response of individual breast cancers to chemotherapy.
采用肾包膜下接种法（SRCA）研究乳腺癌对细胞生长抑制药物联合治疗的敏感性，并将结果与类固醇受体状态进行比较。46例SRCA中有45例（98%）可进行宏观评估。然而，一项组织学研究表明，移植组织也应进行组织学评估，因为在所检查的21例对照SRCA中，只有14例（67%）可见组织学上存活的肿瘤细胞。半数病例出现炎症细胞反应。在仅接受细胞生长抑制药物治疗的组中，只有3/21（14%）有存活的肿瘤细胞，而4/21（19%）的病例有明显炎症。对阿霉素 + 环磷酰胺（A + CTX）的耐药率为30%。通过针对每个肿瘤测试几种药物联合方案，化疗耐药率降至10%。A + CTX与最佳联合方案之间的差异具有统计学意义（P < 0.05）。79%的肿瘤雌激素受体（ER）呈阳性，67%的肿瘤孕激素受体（PR）呈阳性。受体阴性的肿瘤比受体阳性的肿瘤对细胞生长抑制药物更敏感（100%对85%）。然而，差异无统计学意义。可以得出结论，在标准化条件下，SRCA是研究个体乳腺癌对化疗反应的良好方法。
